Search

Author/Creator Balea, Marius

1. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Issue 6 (June 2022)

Authors:
Dimopoulos, Meletios A; Richardson, Paul G; Bahlis, Nizar J; Grosicki, Sebastian; Cavo, Michele; Beksaç, Meral; Legieć, Wojciech; Liberati, Anna M; Goldschmidt, Hartmut; Belch, Andrew; Magen, Hila; Larocca, Alessandra; Laubach, Jacob P; Petrucci, Maria T; Reece, Donna; White, Darrell; Mateos, Mar...
Journal:
Lancet
Issue:
Volume 9:Issue 6(2022)
Page Start:
e403
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms – a multicentric study on 529 patients. (7th April 2016)

Authors:
Trifa, Adrian P.; Bănescu, Claudia; Tevet, Mihaela; Bojan, Anca; Dima, Delia; Urian, Laura; Török‐Vistai, Tünde; Popov, Viola M.; Zdrenghea, Mihnea; Petrov, Ljubomir; Vasilache, Anca; Murat, Meilin; Georgescu, Daniela; Popescu, Mihaela; Pătrinoiu, Oana; Balea, Marius; Costache, Roxana; Coleș, Ele...
Journal:
British journal of haematology
Issue:
Volume 174:Number 2(2016)
Page Start:
218
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search